Pepteligence
Share
Medical notice — For research and educational purposes only. Not medical advice. Consult a licensed physician before using any peptide or compound.

TB-500

healingrecoveryinflammation
Regulatory status — Research use only — not approved for human use

TB-500 is a synthetic peptide corresponding to the N-terminal acetylated 17–23 amino acid fragment of thymosin beta-4 (Ac-LKKTETQ). Preliminary in vitro and animal data suggest roles in actin binding, cell migration, angiogenesis, and wound healing, but no human clinical trials have been conducted and no regulatory approval exists for any indication. It is classified as a prohibited substance by WADA.

Evidence coverage

20/28 claims verified by independent fact-checker.

1 claim pending coverage
  • Src:f3d17e0f-08e8-4985-a22c-3096ca007f68 is titled 'Comparative effects of dietary sodium butyrate and tributyrin on broiler chickens' performance, gene expression, intestinal histomorphometry, blood indices, and litter.' This appears to be an entirely unrelated poultry nutrition study. The UUID exists in the packet but the source almost certainly does not support any claim about TB-500 structure. This is a critical citation mismatch — likely a wrong UUID assigned to this source slot. Claim fails: cited source does not plausibly support the claim.(1 claim)

Pepteligence regenerates entries quarterly and when new high-tier evidence appears.

Quick facts

Half-life
—
Typical dose
See research context
Route
[insufficient evidence in research packet]
Frequency
[insufficient evidence in research packet]
Cycle length
—
Evidence strength
Animal models

Suggested labs for this peptide class — educational reference only; not medical advice.

TL;DR

  • Half-life: — — dosed —.
  • Administered via —.
  • Evidence base: animal model studies.
  • Primary goals: healing, recovery, inflammation.
EVIDENCE HIERARCHYRCTsObservationalAnimal studiesAnecdotal

Primarily animal data

How we evaluate evidence →

How it works

BPC-157 acts on multiple parallel pathways — this multi-system action underlies its broad tissue repair profile.

TB-500 is a synthetic, N-terminal acetylated form of the 17–23 fragment of thymosin beta-4, with the sequence Ac-LKKTETQ [8][3][2][1]. In vitro and mechanistic studies indicate that this fragment may promote actin binding, cell migration, wound healing, angiogenesis, keratinocyte migration, and collagen deposition, while preliminary evidence suggests it may also reduce local inflammation [3][2]. Mechanistic reviews of therapeutic peptides in orthopaedics note that compounds in this class may engage signalling pathways including PI3K/Akt, mTOR, MAPK, TGF-β, and AMPK, though direct confirmation of these pathways for TB-500 in human tissue is not established [4]. In vitro metabolic studies demonstrate that TB-500 undergoes significant metabolic transformation in human kidney microsomes and related in vitro metabolic systems, suggesting rapid enzymatic degradation [7]. All mechanistic evidence is derived from in vitro or animal models; no human pharmacokinetic or pharmacodynamic data are available in the current research packet.

What the research says

Research summary content coming soon. Check the references section for indexed studies.

100%50%25%0%00h1t½0h2t½0h3t½0h4t½0h
Approximate plasma concentration over 4 half-lives (0h × 4 = 0h)

Protocol lifecycle

BeforeDuringAfter

Before — Pre-cycle readiness

Readiness checklist

Evidence awareness
  • Understand that all available mechanistic evidence for TB-500 is derived from in vitro and animal studies only — no human efficacy, safety, or pharmacokinetic data exist.
  • Be aware that TB-500 is a WADA-prohibited substance; competitive athletes face career-affecting sanctions [5][6].
  • Consult a licensed physician before considering any unapproved peptide; no prescribing-label or approved indication exists for TB-500.
Regulatory and legal
  • Confirm the legal status of TB-500 in your jurisdiction — it is not approved by the FDA, EMA, or any identified regulatory body for human use.
  • Verify that any supplier compound has undergone independent third-party purity and sterility testing.
  • No evidence-based pre-cycle guidance exists for TB-500 in humans; the research packet contains no human clinical trial protocols.

During — Active protocol

Protocol notice — The following describes common protocols reported in research and community sources. This is not medical advice. Dosing, frequency, and duration should be determined with a licensed physician familiar with peptide research.
  • No evidence-based monitoring or dosing guidance exists for TB-500 in humans.
  • Athletes subject to WADA-governed testing should be aware that validated detection methods for TB-500 and its metabolites in urine and plasma exist and are in active use [3][2][5].

After — Post-cycle

  • No evidence-based post-cycle or washout guidance exists for TB-500 in humans.

Stacks it appears in

TB-500 is typically used as a standalone compound. Stack data coming soon.

Related peptides

Other compounds indexed on Pepteligence that share research tags with TB-500. Educational context only.

BPC-157

Tier 3
healingrecoveryinflammation

Thymosin Alpha-1

Tier 3
inflammation

DSIP

Tier 2
recovery

CJC-1295

Tier 3
recovery

Safety

Common side effects

  • ·[insufficient evidence in research packet — no human adverse event data identified]

Rare side effects

  • ·[insufficient evidence in research packet]
Safety notice — Serious / theoretical risks:
  • [insufficient evidence in research packet — the absence of human safety data means serious risks cannot be characterised or excluded]

Contraindications

  • ·[insufficient evidence in research packet — no human contraindication data identified]

Community experiences

Community content — User-submitted experiences are self-reported and have not been verified. They do not constitute medical advice. Pepteligence aggregates community data under Section 230 protections.

No community experiences yet for TB-500. Be the first to share yours.

Share your experience →

Have you tried TB-500?

Share your protocol and outcome to help build the community dataset.

Share your experience →

TB-500 — at a glance

PropertyTB-500—
Half-life——
Route——
Typical doseSee research context—
MechanismTB-500 is a synthetic, N-terminal acetylated form of the 17–23 fragment of thymosin beta-4, with the sequence Ac-LKKTETQ. In vitro and mechanistic studies indicate that this fragment may promote actin binding, cell migration, wound healing, angiogenesis, keratinocyte migration, and collagen deposition, while preliminary evidence suggests it may also reduce local inflammation. Mechanistic reviews of therapeutic peptides in orthopaedics note that compounds in this class may engage signalling pathways including PI3K/Akt, mTOR, MAPK, TGF-β, and AMPK, though direct confirmation of these pathways for TB-500 in human tissue is not established. In vitro metabolic studies demonstrate that TB-500 undergoes significant metabolic transformation in human kidney microsomes and related in vitro metabolic systems, suggesting rapid enzymatic degradation. All mechanistic evidence is derived from in vitro or animal models; no human pharmacokinetic or pharmacodynamic data are available in the current research packet.—
Evidence strengthanimalanecdotal
Primary goalhealing—

Frequently asked questions

What is TB-500?
TB-500 is a synthetic peptide corresponding to the N-terminal acetylated 17–23 amino acid fragment of thymosin beta-4 (sequence Ac-LKKTETQ). Preliminary in vitro and animal data suggest roles in actin binding, cell migration, angiogenesis, and wound healing. No human clinical trials have been conducted. It is not FDA-approved.
How does TB-500 work?
In vitro and mechanistic studies indicate that this thymosin beta-4 fragment may promote actin binding, cell migration, wound closure, and angiogenesis. These mechanistic findings come from cell culture and animal models — no controlled human trials have validated these pathways.
Is TB-500 the same as Thymosin Beta-4?
No. TB-500 is not identical to Thymosin Beta-4. It is a synthetic fragment — specifically the acetylated 17–23 amino acid segment (Ac-LKKTETQ) of the full 43-amino acid thymosin beta-4 protein. The two compounds share structural overlap but differ in composition and pharmacology.
What is TB-500 used for?
Preclinical research has investigated TB-500 for potential roles in tissue repair, wound healing, and angiogenesis based on its structural relationship to thymosin beta-4. No controlled human clinical trials have established efficacy or safety for any indication.
Is TB-500 FDA-approved?
No. TB-500 is not FDA-approved for any indication. It is classified as a research compound with no human trial evidence supporting its use.
What are common dosages of TB-500?
No validated human clinical dosing data exist for TB-500. No approved or consensus dose has been identified from the available research literature.
How is TB-500 administered?
No validated route of administration has been established for TB-500 in human clinical research. The research packet documents insufficient evidence to confirm a route based on human trial data.
What are common side effects of TB-500?
No controlled human clinical trial data exist to characterize TB-500's side-effect profile. Its safety in humans is entirely unknown.
Are there safety concerns with TB-500?
No human contraindication data have been identified for TB-500. The complete absence of human trial data means no conclusions about safety in any population can be drawn.
Is TB-500 legal?
TB-500 is not FDA-approved and is not a scheduled controlled substance in the United States. Its legal status for possession and sale varies by jurisdiction. This is not legal advice.
Can TB-500 be combined with other peptides?
No evidence-supported combination protocols have been established for TB-500. The current source literature does not document any stacking combinations with human-validated data.
What does the research on TB-500 show overall?
TB-500's research base consists of in vitro and animal experiments exploring its structural role in actin dynamics, cell migration, and tissue repair as a thymosin beta-4 fragment. No controlled human clinical trials have been conducted. Extrapolating these preclinical findings to human outcomes is premature.

References

  1. [1]

    Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential.

    Esposito Simone, Deventer Koen, Goeman Jan et al.

    Drug testing and analysis · 2012 · PMID 22962027

  2. [2]

    Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry.

    Ho Emmie N M, Kwok W H, Lau M Y et al.

    Journal of chromatography. A · 2012 · PMID 23084823

  3. [3]

    Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro.

    Rahaman Khandoker Asiqur, Muresan Anca Raluca, Min Hophil et al.

    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2024 · PMID 38382158

  4. [4]

    Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

    Rahman Omar F, Lee Steven J, Seeds William A

    Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026 · PMID 41490200

  5. [5]

    Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.

    Thomas Andreas, Görgens Christian, Guddat Sven et al.

    Journal of separation science · 2016 · PMID 26578461

  6. [6]

    Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions.

    Thevis Mario, Thomas Andreas, Schänzer Wilhelm

    Expert review of proteomics · 2014 · PMID 25382550

  7. [7]

    Comparison of various in vitro model systems of the metabolism of synthetic doping peptides: Proteolytic enzymes, human blood serum, liver and kidney microsomes and liver S9 fraction.

    Zvereva Irina, Semenistaya Ekaterina, Krotov Grigory et al.

    Journal of proteomics · 2016 · PMID 27569051

  8. [8]

    Comparative effects of dietary sodium butyrate and tributyrin on broiler chickens' performance, gene expression, intestinal histomorphometry, blood indices, and litter.

    Ismael Elshaimaa, Kamel Shaimaa, Elleithy Ebtihal M M et al.

    Scientific reports · 2025 · PMID 40681595

  9. [?]

    Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

    Mavrych Volodymyr, Shypilova Inna, Bolgova Olena

    Frontiers in aging · 2026 · PMID 42021992

  10. [?]

    Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

    Mendias Christopher L, Awan Tariq M

    Sports medicine (Auckland, N.Z.) · 2026 · PMID 41966639

  11. [?]

    Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

    Mayfield Cory K, Bolia Ioanna K, Feingold Cailan L et al.

    The American journal of sports medicine · 2026 · PMID 41476424

  12. [?]

    Adsorption effects of the doping relevant peptides Insulin Lispro, Synachten, TB-500 and GHRP 5.

    Judák Péter, Van Eenoo Peter, Deventer Koen

    Analytical biochemistry · 2017 · PMID 28887173

  13. [?]

    Solid-phase extraction of small biologically active peptides on cartridges and microelution 96-well plates from human urine.

    Semenistaya Ekaterina, Zvereva Irina, Krotov Grigory et al.

    Drug testing and analysis · 2016 · PMID 26472487

  14. [?]

    In vitro models for metabolic studies of small peptide hormones in sport drug testing.

    Esposito Simone, Deventer Koen, Geldof Lore et al.

    Journal of peptide science : an official publication of the European Peptide Society · 2015 · PMID 25469748

  15. [?]

    Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls.

    Thevis Mario, Schänzer Wilhelm

    Journal of pharmaceutical and biomedical analysis · 2014 · PMID 24906629

  16. [?]

    Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry.

    Kwok Wai Him, Ho Emmie N M, Lau Ming Yip et al.

    Analytical and bioanalytical chemistry · 2013 · PMID 23318763

Compare TB-500 with…

BPC-157 vs TB-500

BPC-157 · TB-500

View comparison →